Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.
about
Current and emerging azole antifungal agentsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePhaeohyphomycosis from Exphiala jeanselmei with concomitant Nocardia asteroides infection in a renal transplant recipient: case report and review of the literature.The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancyIn vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsAntifungal pharmacodynamics: review of the literature and clinical applications.Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasisItraconazole.Intravenous itraconazole.Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Itraconazole (Sporanox) in superficial and systemic fungal infections.Antifungal activity improved by coproduction of cyclodextrins and anabaenolysins in CyanobacteriaAntifungal therapeutic drug monitoring: established and emerging indications.Safety of triazole antifungal drugs in patients with cancer.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Current concepts in antifungal pharmacology.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityDried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.Solubility parameter-based screening methods for early-stage formulation development of itraconazole amorphous solid dispersions.Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy.Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
P2860
Q24550733-23896511-86C3-47E5-922C-71F94DBB72A8Q27009221-716382CC-DD3A-4C84-89F6-B777E604FFCFQ33715935-33E208BF-2F8C-4D2F-929E-50F276669D66Q33788619-8716B4EC-6ECB-440D-AC28-638858598ADAQ33894467-BE3F36B3-8A77-4684-8862-D1406B111486Q33981794-86D73B3E-E4FF-475C-8CFF-286D90149A55Q34041745-4C3BFB83-8BE0-4D35-B578-E88637616350Q34083129-77600670-296C-4199-A783-E79D325C8A26Q34111158-153D4AAA-D2C1-4B81-AA7C-498D789D12F1Q34182267-C10CB38B-C5E6-4FC3-85A2-6864DCB77FD0Q34284268-CD351466-B870-4CD4-B893-0EE69A06BA67Q34291656-73148659-113C-4A20-A445-CAF1E54B32A0Q34505582-76D474A0-E612-4A0E-9870-4B5AB1D597B6Q35557331-790BCA1B-163B-4864-9CE3-0659307B8C58Q35647678-2443E906-52BC-4471-82E1-DF08B4ABD2A6Q35917270-8BB09D4A-C27A-4E96-8694-8F177279F7ABQ36268594-7D0A5289-49E2-4A82-AA90-1119F5292B9AQ37310029-5D543929-975C-484F-95BF-057E934D2898Q37662650-AD0E1EDE-CC8D-408C-B77A-D3E393F85254Q37688257-25FD7A11-21AA-4185-BD2C-A6CF873CDCF0Q37904672-19E9256F-FC79-4811-A321-A72A046C9D47Q37908856-F2A49824-88FA-4429-9A8D-79AD7661577CQ38103889-F4D90808-B524-43FB-AF6F-AE3623EB4E09Q38193337-CE414641-98D9-4241-8191-9C184CC0F1BFQ38738090-A42EA153-F84C-43E5-AEE6-D4759559DF9BQ39558155-BC47FBA8-BF97-40F7-80BF-54D0926B8155Q41991703-D8AFD62A-1776-426B-A731-8CF45D678952Q42930341-D0CF476E-CA81-4382-A185-975D3484216AQ51529712-F73E23E5-E43E-4C62-94A1-63AA9ECEC116Q53703714-C158B29F-EE69-48FB-A51E-EBB212BCD8F7Q58719932-0DC196F8-43E9-4B3D-9FD7-E415CE81C58C
P2860
Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Itraconazole solution: higher ...... rome patients with candidosis.
@en
Itraconazole solution: higher ...... rome patients with candidosis.
@nl
type
label
Itraconazole solution: higher ...... rome patients with candidosis.
@en
Itraconazole solution: higher ...... rome patients with candidosis.
@nl
prefLabel
Itraconazole solution: higher ...... rome patients with candidosis.
@en
Itraconazole solution: higher ...... rome patients with candidosis.
@nl
P2093
P2860
P356
P1476
Itraconazole solution: higher ...... rome patients with candidosis.
@en
P2093
Cartledge JD
Gazzard BG
P2860
P304
P356
10.1136/JCP.50.6.477
P407
P577
1997-06-01T00:00:00Z